131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinistat
Phase: Phase 2
DFCI Protocol ID: 14-184
This study will compare three treatment regimens containing metaiodobenzylguanidine (MIBG) and compare their effects on tumor response and associated side effects, to determine if one therapy is better than the other for people diagnosed with relapsed or persistent neuroblastoma.
Children's Hospital Boston, Dana-Farber Cancer Institute
Suzanne Shusterman, MD,
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute:
Childrens Hospital Pediatric Clinical Translation Investigation Program CTIP, email@example.com
- Patients must be > 24 months and < 30 years of age when registered on study.
- Patients must have relapsed neuroblastoma, refractory neuroblastoma that had less
than a partial response to standard treatment or persistent neuroblastoma that had at
least a partial response to frontline therapy frontline therapy with > 3 residual
lesions on end-induction MIBG scan.
- Patients must have evidence of MIBG uptake into tumor at ≥ one site within 4 weeks
prior to entry on study and subsequent to any intervening therapy.
- Patients must have adequate heart, kidney, liver and bone marrow function. Patients
who have bone marrow disease must still have adequate bone marrow function to enter
- Patients must have a dose of unpurged peripheral blood stem cells is 2.0 x 106 viable
CD34+ cells/kg available.
- They have had previous I-131 MIBG therapy
- They have other medical problems that could get much worse with this treatment.
- They are pregnant or breast feeding.
- They have a history of a venous or arterial thrombosis that was not associated to a
- They have active infections such as hepatitis or fungal infections.
- They have active diarhhea.
- They have had an allogeneic stem cell transplant (received stem cell from someone
- They can't cooperate with the special precautions that are needed for this trial.